MEDICAL

DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus

DxTerity | June 13, 2022

Dx_Terity_Diagnostics
DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus.

DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an increased risk for the development of lupus nephritis in SLE patients. The DxTerity IFN-1 Test is the first commercial IFN-1 gene expression assay.

Patients living with lupus can find it difficult to predict and interpret symptoms. Each person's experience is unique and not all patients respond to standard treatments. Disease symptoms and treatment failure may be the result of a person's specific genomic activity. The DxTerity IFN-1 Test measures the expression levels of 4 genes associated with IFN-1 activity and identifies a patient as IFN-1 high or low. This information can be used by a healthcare provider to guide treatment.

Rheumatologists have long been faced with limited therapy options for lupus management. With the recent FDA approval and availability of the Type-1 Interferon receptor blocking therapy anifrolumab (Saphnelo®), lupus patients have a new and much needed treatment option.

We are excited to launch the DxTerity IFN-1 Test, the first available IFN-1 gene signature test to provide information regarding a person's unique genomic activity, It is our mission to transform patient care by developing diagnostic tools that support a personalized approach to the treatment of immune-mediated disease."

Bob Terbrueggen, Ph.D., Founder and CEO of DxTerity Diagnostics.

About DxTerity
DxTerity Diagnostics is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory based near Los Angeles, CA. DxTerity Diagnostics develops simple, fast, and affordable genomic tests for disease diagnosis and disease monitoring.


Spotlight

Terra Biotech, a lead nutritional supplement company, has partnered with Feeding the Orphans to facilitate the delivery of its Nectr Core vitamin powder, a nutrient-dense super food product, to malnourished children in regions of Africa and Haiti.

Spotlight

Terra Biotech, a lead nutritional supplement company, has partnered with Feeding the Orphans to facilitate the delivery of its Nectr Core vitamin powder, a nutrient-dense super food product, to malnourished children in regions of Africa and Haiti.

Related News

INDUSTRIAL IMPACT

Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target

Orion Biotechnology | July 15, 2022

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target. The collaboration will combine the capabilities of Peptilogics’ AI platform (NautilusTM) with Orion Biotechnology’s proprietary drug discovery platform. The companies will leverage expertise in peptide design and engineering to drive drug discovery against an undrugged peptidergic GPCR linked to highly prevalent, life-threatening diseases. Peptilogics’ Nautilus™ platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom-design therapeutics. Additionally, Peptilogics’ supercomputer accelerates model development, prediction and evaluation of peptide sequences to produce higher quality hits with greater chance of success. Synergistically, Orion Biotechnology’s platform explores receptor-ligand shape space using proprietary multiplex synthesis technology to generate precision-engineered peptides with enhanced potency and tailored signaling activity. Orion’s platform generates data matrices for AI-assisted lead optimization, offering one of the fastest drug discovery and development solutions to target peptidergic GPCRs. On the announcement of this collaboration, Dr. Oliver Hartley, VP Drug Discovery at Orion Biotechnology, commented, “We are pleased to be partnering with Peptilogics to push the boundaries of receptor pharmacology and AI computing to accelerate innovation for improved patient outcomes. An AI-driven paradigm shift is happening in drug discovery, and Orion is pleased to be at the forefront of applying AI to the highly valuable space around GPCRs. The ideal fit between Orion’s platform and unique knowledge of receptor-ligand interactions with Peptilogics’ machine learning models will position us to make AI-driven GPCR drug discovery a reality.” “Using Peptilogics’ Nautilus™ platform, we combine proprietary deep generative models, predictive models and biophysical simulation to design multiparameter-optimized peptides that have the potential to address historically challenging and novel drug targets. Our AI algorithms enable efficient navigation of the vast peptide design space, allowing us to uncover molecules that may not be discovered through traditional screening. We are excited to partner with Orion Biotechnology for their deep GPCR expertise. By combining the strengths of Peptilogics’ Nautilus™ AI-driven peptide design platform and Orion’s GPCR platform, we aim to reduce the risk, time and cost for drug design.” Nicholas Nystrom, Ph.D., Chief Technology Officer of Peptilogics About Orion Biotechnology Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs). Orion’s world-renowned experts in GPCR pharmacology and peptide/protein engineering leverage Orion’s proprietary drug discovery platform to rapidly and efficiently advance a diversified portfolio of precision engineered GPCR-targeted therapeutic candidates for the treatment of cancer and other serious diseases. About Peptilogics Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation.

Read More

INDUSTRIAL IMPACT

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy PsyAITM, our proprietary artificial intelligence tool, and PsybraryTM, our expanding proprietary portfolio of new chemical entities and drug candidates, to design and improve upon new drug molecules inspired by legacy psychedelic drugs,” Dr. Joseph Tucker, PhD, Enveric’s Chief Executive Officer “Enveric is pleased to advise that our predictions have materialized, and our platforms have successfully generated a large number of promising new molecules that have successfully passed primary screening and moved on to lead optimization, providing us with a strong slate of drug candidates. Our leading program, EVM-201, includes a number of new molecules currently in lead optimization that are geared towards providing improved characteristics and drug-like properties compared with psilocybin. The successful outcomes from our testing efforts completed in the first half of 2022 have positioned the company very well to advance our drug candidates towards the clinic,” continued Dr. Tucker. Clinical-Need Driven Based on extensive direct clinical understanding of the current unmet needs in anxiety, depression, PTSD, and other mental health indications, coupled with in-depth knowledge of the current treatment landscape, Enveric’s Clinical Team is well positioned to tackle the challenges ahead, while aiming to shepherd novel new treatments for a host of mental health indications. Enveric’s Clinical Team is led by a past Board-certified psychiatrist and clinical trialist Chief Medical Officer, Dr. Bob Dagher, MD. Dr. Dagher joined Enveric in December 2021, bringing a wealth of clinical trial management and new CNS-drug development experience from his past roles, including at WCG, Cadent, Covance, Sanofi and GSK, in addition to his first-hand experience in treating patients from his previous clinical practice in psychiatric medicine. Next-Generation Drug Discovery Enveric’s Discovery Team, spearheaded by Chief Innovation Officer Dr. Peter Facchini, PhD, an international leader in natural product biochemistry and biotechnology, completed the rational design of more than 300 Generation-2 (“Gen-2”) psilocin prodrug candidates using well-established design strategies, but adapted to the unique structure of psilocin. The 300 Gen-2 original concept designs, now housed within the PsybraryTM, were screened using PsyAITM. The assessment helped predict chemical structures with appropriate receptor binding, toxicology, and pharmacokinetic profiles that would trigger the desired mechanisms of action while reducing undesirable side effects, and the initial candidate evaluation included, among other metrics, prodrug-likeness, toxicity, ease of chemical synthesis and degree of IP-white space surrounding the molecule. Ranked scoring of these and other AI assessments, as well as commercial considerations (e.g., ease of procuring synthetic starting materials), prioritized 31 novel Gen-2 molecules that have been synthesized in sufficient quantities (~10 mg, 95% purity) for preliminary pharmacological screening. Enveric’s Chemistry Group, led by Dr. Kaveh Matinkhoo, PhD, completed these syntheses, 29 of which were deemed stable enough to advance. Deep-dive chemical structure searches, patentability, and freedom-to-operate reviews were performed on all 29 candidates, under the leadership of Lead Internal Counsel C. Michael Gegenheimer. All the patentability analyses indicated potential patentability results, and 25 of the 29 molecules presented minimal concern with freedom to operate. To strengthen the IP protection for the overall Gen-2 prodrug program, three provisional patent applications, covering 7 structurally diverse clinical classes and thousands of additional potential new drug candidates, have been filed so far in 2022, and additional provisional and PCT filings are expected to continue throughout the year. In other IP developments, an additional three of Enveric’s international patent applications protecting tryptamine derivatives have been published by the World Intellectual Property Organization, bringing the total published so far to seven. EVM-201 Drug Candidate Testing Following the initial Gen-2 ideation, patent filing, synthesis, and screening efforts, more extensive assays were performed on the advancing drug candidates. Numerous internal assays were performed under the leadership of Dr. Jill Hagel, PhD, Vice-President of Innovation and Dr. Sheetal Raithatha, PhD, Director of Research and Development. The internal results were then confirmed and validated using leading independent, third-party Contract Research Organizations (CROs), covering 122 Toxicology tests, 72 receptor-binding and potency tests, 31 pharmacokinetic tests and 24 animal-model tests to provide ample information to support candidate nomination. The synthesis and analysis of these comprehensive pharmacology and toxicology datasets, both internal and external, was led by Dr. Kevin Leach, PhD DABT, Vice President of Preclinical and Translational Research. Enveric is now moving towards lead-candidate nomination and, in preparation for IND filing, has initiated numerous IND-enabling studies on several of the leading candidates at third-party CROs. Recognizing the need for stable drugs with robust, reproducible, and cost-effective manufacturing, several Contract Development & Manufacturing Organizations (CDMOs) are currently engaged with Enveric’s Chemistry Team to determine how best to manufacture our molecules. Enveric has plans in place to produce material at commercial facilities and the CDMO personnel have worked with our chemists to validate that our processes will work at their facilities. This is another necessary step prior to filing the IND. Finally, preliminary formulation work is underway, with a particular focus on enabling improved routes of administration. “The first half of the year has indeed been busy and productive for the dedicated team here at Enveric. We are all very excited at how those efforts have begun to bear fruit. We look forward to advising our shareholders of further key developments, which we anticipate will continue to unfold during the remainder of 2022,” concluded Dr. Tucker. About Enveric Biosciences Enveric Biosciences, Inc. is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric's robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more.

Read More

INDUSTRIAL IMPACT

Ecological Laboratories, Inc. announces acquisition of TOMCO Chemical to Bolster Reach into Hog Farming Waste Management.

Ecological Laboratories, Inc. | July 08, 2022

Ecological Laboratories, Inc. a Biotechnology company that develops and manufactures novel, proprietary, liquid microbial formulations capable of solving many of the most challenging environmental problems, announced that it has acquired TOMCO Chemical. TOMCO Chemical has provided bacterial products specifically to breakdown solids and reduce odors for Hog Farms in the United States. "We are thrilled to bring together the TOMCO team with Ecological, which gives us critical mass to research, support and deliver against producer's farm waste challenges today and tomorrow." Ecological's CEO Nick Favret Ecological Laboratories, Inc. has been servicing the Hog Farming Waste Management Industry for more than forty years. By acquiring TOMCO, Ecological will be able to reach more farming leaders looking to use Biologically friendly solutions moving forward. TOMCO's premier product Pit-Perfect, a component of their In-Gest-O-Bac product series has been a tool used by farmers with great success. As Bio-Gas and Sustainable Agriculture continue to scale globally, Ecological recognizes the further demand of their microbial solutions. Ecological's Farm Waste Management solutions under the brand MICROBE-LIFT is the most effective way to improve farm waste processes. With unmatched capabilities to breakdown waste, and reduce toxic gases. MICROBE-LIFT technology drives down costs, increases operation efficiency, provides return on investment and supports regulatory compliance. "I am proud to announce the merger of TOMCO Chemical and Ecological Laboratories, Inc. By joining forces with Ecological we have the capacity to bring the best solution in waste management to a level that has not been seen before", said Tom Elsner President & CEO of TOMCO Chemical. Ecological Laboratories, Inc. continues to innovate with our propriety microbial formulations focusing on solutions for the Commercial Waste Water, Farm Waste, Aquaculture, Composting, Eco-System Restoration and Bio Gas Industries as well as the Retail Water Garden, Lawn and Garden, Aquarium, Pet, Hydroponic and Septic markets.

Read More